Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-Marketing Observational Study to Evaluate Safety and Effectiveness of Upadacitinib in Adolescent Patients Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)

NCT05029895 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05029895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05029895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-Marketing Observational Study to Evaluate Safety and Effectiveness of Upadacitinib in Adolescent Patients Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
September 29, 2021
Completion date
September 17, 2025
Enrollment
167 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis